ProCE Banner Activity

Are We Close to Curing HBV?

Conference Coverage
Clinical Thought
My thoughts on which HBV cure strategies might be fruitful.

Released: July 22, 2021

Expiration: July 21, 2022

No longer available for credit.

Share

Faculty

Robert G. Gish

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Supporters

AbbVie

Antios Therapeutics

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven, Genentech, Genlantis, Gilead Sciences, Hepatx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, and Viking; has served on advisory boards for Abbott, AbbVie, Antios, Arrowhead, Bayer, BioCollections, Dova, Eiger, Enyo, Fibronostics, Fujifilm/Wako, Gilead Sciences, HepQuant, Intercept, Janssen, Merck, Prodigy, and Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, and CymaBay.